Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INTENSITY THERAPEUTICS, INC. (INTS)

Intensity Therapeutics Q1 2026 net loss narrows to $2.4 million from $3.3 million

Positive Impact 3 of 5 earnings Written later

Intensity Therapeutics reported a first quarter 2026 net loss of $2.4 million, down from $3.3 million a year earlier, as research and development expenses fell to $1.2 million from $2.2 million. Cash and cash equivalents were $10.2 million at March 31, 2026, down from $11.9 million at December 31, 2025, and the company said it will resume enrollment in its INVINCIBLE-3 Phase 3 trial, which had been paused for funding reasons, by the third quarter of 2026.

Key points

  • Net loss was $2.4 million for the three months ended March 31, 2026, versus $3.3 million a year earlier
  • Research and development expenses were $1.2 million, down from $2.2 million, mainly due to lower INVINCIBLE-3 Study costs
  • General and administrative expenses rose to $1.3 million from $1.2 million, driven by an estimated bonus accrual
  • Cash and cash equivalents were $10.2 million at March 31, 2026, versus $11.9 million at December 31, 2025

The filing

CompanyINTENSITY THERAPEUTICS, INC. (INTS)
Form8-K, current report
Filed with the SECMay 7, 2026, 4:10 PM ET
Accession number0001567264-26-000047

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.